{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:52:09Z","timestamp":1794379929514,"version":"4.9.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"am","delay-in-days":196,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jbspin.2023.105627","type":"journal-article","created":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T11:15:53Z","timestamp":1693048553000},"page":"105627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Type 1 interferons: A target for immune-mediated inflammatory diseases (IMIDs)"],"prefix":"10.1016","volume":"91","author":[{"given":"Alexis","family":"Mathian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-4032","authenticated-orcid":false,"given":"Renaud","family":"Felten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta E.","family":"Alarcon-Riquelme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Psarras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9781-7388","authenticated-orcid":false,"given":"Philippe","family":"Mertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2580-8607","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Chasset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Vital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8077-8394","authenticated-orcid":false,"given":"Laurent","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2023.105627_bib0295","first-page":"1662","article-title":"interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy","volume":"56","author":"Psarras","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2023.105627_bib0300","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20969261","article-title":"Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis","volume":"12","author":"Petitdemange","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.jbspin.2023.105627_bib0305","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1136\/annrheumdis-2018-213386","article-title":"Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status","volume":"77","author":"Md Yusof","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105627_bib0310","unstructured":"Predicting progression from undifferentiated connective tissue disease to definite connective tissue disease: a systematic review and meta-analysis\u00a0\u2013\u00a0PubMed n.d. https:\/\/pubmed.ncbi.nlm.nih.gov\/36031048\/. (accessed June 20, 2023)."},{"key":"10.1016\/j.jbspin.2023.105627_bib0315","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2147\/DDDT.S170969","article-title":"Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date","volume":"13","author":"Felten","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jbspin.2023.105627_bib0320","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1086\/428480","article-title":"Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus","volume":"76","author":"Sigurdsson","year":"2005","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jbspin.2023.105627_bib0325","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1038\/s41467-022-30773-y","article-title":"Genome-wide association study identifies Sj\u00f6gren's risk loci with functional implications in immune and glandular cells","volume":"13","author":"Khatri","year":"2022","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.jbspin.2023.105627_bib0330","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/art.42265","article-title":"Variability of primary Sj\u00f6gren's syndrome is driven by interferon \u03b1 and interferon \u03b1 blood levels are associated with the class II HLA\u2013DQ locus","volume":"74","author":"Trutschel","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105627_bib0335","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/art.41610","article-title":"Integrative analysis reveals a molecular stratification of systemic autoimmune diseases","volume":"73","author":"Barturen","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105627_bib0340","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coi.2014.10.005","article-title":"Type I interferonopathies: mendelian type I interferon up-regulation","volume":"32","author":"Crow","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jbspin.2023.105627_bib0345","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaut.2009.03.006","article-title":"Autoimmunity and Klinefelter's syndrome: when men have two X chromosomes","volume":"33","author":"Sawalha","year":"2009","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jbspin.2023.105627_bib0350","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM197907053010102","article-title":"Immune interferon in the circulation of patients with autoimmune disease","volume":"301","author":"Hooks","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2023.105627_bib0355","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.jbspin.2023.105627_bib0360","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.38628","article-title":"Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures","volume":"66","author":"Chiche","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105627_bib0365","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2023.105627_bib0370","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1136\/ard.2004.033753","article-title":"Type I interferon correlates with serological and clinical manifestations of SLE","volume":"64","author":"Dall\u2019Era","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105627_bib0375","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.40792","article-title":"Monitoring disease activity in systemic lupus erythematosus with single-molecule array digital enzyme-linked immunosorbent assay quantification of serum interferon-\u03b1","volume":"71","author":"Mathian","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105627_bib0380","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/art.22578","article-title":"Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus","volume":"56","author":"Toukap","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105627_bib0385","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0002-9440(10)61689-6","article-title":"Plasmacytoid dendritic cells (natural interferon-\u03b1\/\u03b2-producing cells) accumulate in cutaneous lupus erythematosus lesions","volume":"159","author":"Farkas","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jbspin.2023.105627_bib0390","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1136\/annrheumdis-2018-213197","article-title":"Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa","volume":"77","author":"Sarkar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105627_bib0395","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/s41590-019-0386-1","article-title":"Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways","volume":"20","author":"Der","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jbspin.2023.105627_bib0400","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/art.1780350410","article-title":"Interferon-alpha in lupus psychosis","volume":"35","author":"Shiozawa","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105627_bib0405","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40265-015-0394-x","article-title":"Targeting interferons in systemic lupus erythematosus: current and future prospects","volume":"75","author":"Mathian","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.jbspin.2023.105627_bib0410","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jbspin.2023.105627_bib0415","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev-pathol-020117-043952","article-title":"Type I interferons in autoimmune disease","volume":"14","author":"Crow","year":"2019","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jbspin.2023.105627_bib0420","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-101921-042422","article-title":"Systemic lupus erythematosus pathogenesis: interferon and beyond","volume":"41","author":"Caielli","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jbspin.2023.105627_bib0425","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1182\/blood-2007-05-089086","article-title":"Interferon-\u03b1 promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis","volume":"110","author":"Denny","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2023.105627_bib0430","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1038\/s41467-020-19918-z","article-title":"Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity","volume":"11","author":"Psarras","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jbspin.2023.105627_bib0435","first-page":"575","article-title":"Emerging concepts of type I interferons in SLE pathogenesis and therapy","volume":"18","author":"Psarras","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105627_bib0440","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40262-023-01238-2","article-title":"Clinical pharmacokinetics, pharmacodynamics, and immunogenicity of anifrolumab","volume":"62","author":"Tang","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jbspin.2023.105627_bib0445","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2133.2012.10825.x","article-title":"The IFN-regulated gene signature is elevated in SCLE and DLE and correlates with CLASI score","volume":"166","author":"Braunstein","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jbspin.2023.105627_bib0450","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3390\/jcm8081244","article-title":"Molecular profiling of cutaneous lupus lesions identifies subgroups distinct from clinical phenotypes","volume":"8","author":"Berthier","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.jbspin.2023.105627_bib0455","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1093\/rheumatology\/keaa167","article-title":"for the Swiss SLE Cohort Study (SSCS). Identification of highly active systemic lupus erythematosus by combined type I interferon and neutrophil gene scores vs classical serologic markers","volume":"59","author":"Chasset","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2023.105627_bib0460","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/annrheumdis-2021-221835","article-title":"Serum interferon-\u03b1 levels and IFN type I-stimulated genes score perform equally to assess systemic lupus erythematosus disease activity","volume":"81","author":"Chasset","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105627_bib0465","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105627_bib0470","doi-asserted-by":"crossref","first-page":"105523","DOI":"10.1016\/j.jbspin.2023.105523","article-title":"New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review","volume":"90","author":"Felten","year":"2023","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2023.105627_bib0475","doi-asserted-by":"crossref","first-page":"464","DOI":"10.15252\/emmm.201404719","article-title":"Anti-BDCA 2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms","volume":"7","author":"Pellerin","year":"2015","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jbspin.2023.105627_bib0480","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2023.105627_bib0485","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa2118024","article-title":"Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus","volume":"387","author":"Werth","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2023.105627_bib0490","doi-asserted-by":"crossref","first-page":"eabf8442","DOI":"10.1126\/scitranslmed.abf8442","article-title":"Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus","volume":"13","author":"Karnell","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jbspin.2023.105627_bib0495","first-page":"167","article-title":"TLR-mediated activation of type I IFN during antiviral immune responses: fighting the battle to win the war","volume":"316","author":"Severa","year":"2007","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.jbspin.2023.105627_bib0500","first-page":"1","article-title":"Disturbances of apoptotic cell clearance in systemic lupus erythematosus","volume":"13","author":"Shao","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2023.105627_bib0505","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jbspin.2018.09.004","article-title":"Advances in the treatment of systemic lupus erythematosus: from back to the future, to the future and beyond","volume":"86","author":"Felten","year":"2019","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2023.105627_bib0510","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105627_bib0515","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105627_bib0520","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/S2665-9913(21)00317-9","article-title":"Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials","volume":"4","author":"Morand","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"suppl 10","key":"10.1016\/j.jbspin.2023.105627_bib0525","article-title":"Early and sustained reduction in severity of skin disease with anifrolumab treatment in patients with active SLE measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI): pooled data from 2 phase 3 studies","volume":"72","author":"Werth","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.jbspin.2023.105627_bib0530","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/bjd\/ljad089","article-title":"Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers","volume":"189","author":"Carter","year":"2023","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jbspin.2023.105627_bib0535","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1001\/jamadermatol.2023.0175","article-title":"Assessment of clinical response to anifrolumab in patients with refractory discoid lupus erythematosus","volume":"159","author":"Shaw","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jbspin.2023.105627_bib0540","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaad.2023.02.044","article-title":"Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus","volume":"89","author":"Chasset","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jbspin.2023.105627_bib0545","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105627_bib0550","doi-asserted-by":"crossref","unstructured":"Merrill JT, Tanaka Y, D\u2019cruz D, Vila K, Siri D, Zeng X, et al. OP0139 efficacy and safety of ABBV-599 high dose (elsubrutinib 60 mg and upadacitinib 30 mg) and upadacitinib monotherapy for the treatment of systemic lupus erythematosus: a phase 2, double-blind, placebo-controlled trial 2023.","DOI":"10.1136\/annrheumdis-2023-eular.2402"},{"key":"10.1016\/j.jbspin.2023.105627_bib0555","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105627_bib0560","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard-2022-223628","article-title":"Eloranta M-L et al., 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice","volume":"82","author":"Rodr\u00edguez-Carrio","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105627_bib0565","doi-asserted-by":"crossref","first-page":"e002864","DOI":"10.1136\/rmdopen-2022-002864","article-title":"Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider","volume":"9","author":"Rodr\u00edguez-Carrio","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2023.105627_bib0570","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/annrheumdis-2021-221425","article-title":"Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials","volume":"81","author":"Vital","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105627_bib0575","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1056\/NEJMoa2106535","article-title":"Phase 2 trial of iberdomide in systemic lupus erythematosus","volume":"386","author":"Merrill","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2023.105627_bib0580","doi-asserted-by":"crossref","first-page":"bbac332","DOI":"10.1093\/bib\/bbac332","article-title":"Scoring personalized molecular portraits identify systemic lupus erythematosus subtypes and predict individualized drug responses, symptomatology and disease progression","volume":"23","author":"Toro-Dom\u00ednguez","year":"2022","journal-title":"Brief Bioinform"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X23001069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X23001069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:30:33Z","timestamp":1761150633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X23001069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1297319X23001069"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2023.105627","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type 1 interferons: A target for immune-mediated inflammatory diseases (IMIDs)","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2023.105627","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105627"}}